You have free access to this content

Cancer

Cover image for Vol. 117 Issue 22

15 November 2011

Volume 117, Issue 22

Pages 5023–5246

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      FDA implements new initiatives to ensure drug safety (page 5024)

      Carrie Printz

      Version of Record online: 3 NOV 2011 | DOI: 10.1002/cncr.26641

    3. You have free access to this content
      Bevacizumab recommendation highlights difficulties (page 5025)

      Carrie Printz

      Version of Record online: 3 NOV 2011 | DOI: 10.1002/cncr.26642

  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Making and evaluating a statistical prediction model for the absolute risk of prostate cancer recurrence (pages 5026–5028)

      Michael W. Kattan and Thomas A. Gerds

      Version of Record online: 3 JUN 2011 | DOI: 10.1002/cncr.26174

      Here are provided some general rules and insights for the making of a prediction model for patient counseling. Issues abound regarding what to predict, and how to know if the prediction model works.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Genitourinary Disease
      You have free access to this content
      Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy (pages 5029–5038)

      Andrea Salonia, Andrea Gallina, Alberto Briganti, Nazareno Suardi, Umberto Capitanio, Firas Abdollah, Roberto Bertini, Massimo Freschi, Patrizio Rigatti and Francesco Montorsi

      Version of Record online: 14 APR 2011 | DOI: 10.1002/cncr.26136

      • original image

      In this study, preoperative circulating estradiol levels were associated significantly with a greater incidence of pathologic high-grade prostate cancer. Men with circulating estradiol levels above the most informative cutoff value of 50 pg/mL had higher rates of both advanced pathologic tumor classification and high-grade prostate cancer.

    2. You have free access to this content
      The CAPRA-S score : A straightforward tool for improved prediction of outcomes after radical prostatectomy (pages 5039–5046)

      Matthew R. Cooperberg, Joan F. Hilton and Peter R. Carroll

      Version of Record online: 3 JUN 2011 | DOI: 10.1002/cncr.26169

      • original image
      • original image
      • original image
      • original image

      The Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) score is shown to be a novel instrument for postoperative risk stratification of men after radical prostatectomy. The score can be easily calculated and was found to offer comparable discrimination and improved calibration compared with existing instruments.

    3. Head and Neck Disease
      You have free access to this content
      Patterns of extralaryngeal spread of laryngeal cancer : Thyroid cartilage penetration occurs in a minority of patients with extralaryngeal spread of laryngeal squamous cell cancers (pages 5047–5051)

      Susie A. Chen, Susan Muller, Amy Y. Chen, Patricia A. Hudgins, Dong M. Shin, Fadlo Khuri, Nabil F. Saba and Jonathan J. Beitler

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26130

      • original image
      • original image
      • original image
      • original image

      Extralaryngeal spread of laryngeal squamous cell carcinoma occurs in a variety of pathways. Further characterization of the patterns of spread of stage T4 laryngeal squamous cell carcinoma may allow identification of patients who will have the potential for a functional larynx and, thus, are potential laryngeal preservation candidates.

    4. You have free access to this content
      Distinctive chromosomal instability patterns in oral verrucous and squamous cell carcinomas detected by high-resolution DNA flow cytometry (pages 5052–5057)

      Monica Pentenero, Alessandra Donadini, Emanuela Di Nallo, Massimo Maffei, Roberto Marino, Ubaldo Familiari, Roberto Broccoletti, Patrizio Castagnola, Sergio Gandolfo and Walter Giaretti

      Version of Record online: 16 MAY 2011 | DOI: 10.1002/cncr.26126

      • original image

      Oral verrucous carcinomas (OVC) are characterized by a lower degree of chromosomal instability (CIN) and tumor heterogeneity than oral squamous cell carcinomas (OSCC) such that they appear as “frozen” in an early stage of DNA near-diploid aneuploidy, as previously observed for oral preneoplastic lesions. These DNA Index characteristics, which can easily be obtained by high-resolution DNA flow cytometry, appear to reflect well-known differences in aggressiveness and prognosis of OVCs and OSCCs.

    5. Hematologic Malignancies
      You have free access to this content
      Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell–like than in germinal center B-cell–like phenotype (pages 5058–5066)

      Francisco J. Hernandez-Ilizaliturri, George Deeb, Pier L. Zinzani, Stefano A. Pileri, Farhana Malik, William R. Macon, Andre Goy, Thomas E. Witzig and Myron S. Czuczman

      Version of Record online: 14 APR 2011 | DOI: 10.1002/cncr.26135

      • original image
      • original image
      • original image
      • original image

      In this collaborative effort, the authors evaluated differences in the clinical activity of single-agent lenalidomide in patients with germinal center B-cell–like and nongerminal center B-cell–like diffuse large B-cell lymphoma (DLBCL). The data suggested that patients with relapsed/refractory DLBCL with a nongerminal center B-cell–like phenotype (defined by Hans criteria) have a higher overall response rate (52.9% vs 8.7%, P = .006), higher complete remission rate (23.5% vs 4.3%), and longer progression-free survival (6.2 vs 1.7 months, P = .004) when treated with lenalidomide as compared with those with germinal center B-cell–like phenotype. A large phase 2/3 prospective clinical trial (NCT01197560) is currently accruing patients with relapsed/refractory DLBCL to confirm these initial results.

    6. You have free access to this content
      Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort (pages 5067–5073)

      Tomasz P. Srokowski, James E. Liebmann, Manuel R. Modiano, Gary I. Cohen, Barbara Pro, Jorge E. Romaguera, Christine Kuepfer, Jack W. Singer and Luis E. Fayad

      Version of Record online: 16 JUN 2011 | DOI: 10.1002/cncr.26121

      • original image

      Pixantrone dimaleate is a novel aza-anthracendione with cytotoxic potency in various in vitro tumor models and void of acute or delayed cardiotoxicity in animal models. In this phase 1 trial, with a dose-expansion cohort, pixantrone was well-tolerated and highly active in combination with standard doses of fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent NHL.

    7. You have free access to this content
      Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia (pages 5074–5084)

      Anna Guidetti, Carmelo Carlo-Stella, Marco Ruella, Rosalba Miceli, Lilli Devizzi, Silvia L. Locatelli, Arianna Giacomini, Adele Testi, Stefano Buttiglieri, Alessandra Risso, Luigi Mariani, Massimo Di Nicola, Roberto Passera, Corrado Tarella and Alessandro M. Gianni

      Version of Record online: 12 MAY 2011 | DOI: 10.1002/cncr.26182

      • original image
      • original image
      • original image

      The objective of this study was to investigate the hematopoietic damage and incidence of secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/AML) in patients with non-Hodgkin lymphoma (NHL) who received myeloablative doses of the radiolabeled antibody yttrium-90-ibritumomab tiuxetan. The results indicated that, in elderly patients with NHL, the development of sMDS/AML was not influenced substantially by high-dose radioimmunotherapy.

    8. You have free access to this content
      Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib (pages 5085–5093)

      Alfonso Quintás-Cardama, Hagop Kantarjian, Jianqin Shan, Elias Jabbour, Lynne V. Abruzzo, Srdan Verstovsek, Guillermo Garcia-Manero, Susan O'Brien and Jorge Cortes

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26147

      • original image
      • original image

      Deletions of derivative chromosome 9 have been associated with a poor prognosis in chronic myeloid leukemia across different therapeutic modalities. Imatinib therapy may overcome the poor prognostic impact of deletions of derivative chromosome 9. Patients failing imatinib therapy customarily receive treatment with the second generation tyrosine kinase inhibitors (TKIs) nilotinib or dasatinib. Whether the poor prognostic impact of deletions of derivative chromosome 9 may be overcome by these TKIs is currently unknown.

    9. Hepatobiliary Disease
      You have free access to this content
      Phase 1/2 study of everolimus in advanced hepatocellular carcinoma (pages 5094–5102)

      Andrew X. Zhu, Thomas A. Abrams, Rebecca Miksad, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Hui Zheng, Alona Muzikansky, Jeffrey W. Clark, Eunice L. Kwak, Deborah Schrag, Kathryn R. Jors, Charles S. Fuchs, A. John Iafrate, Darrell R. Borger and David P. Ryan

      Version of Record online: 27 APR 2011 | DOI: 10.1002/cncr.26165

      • original image
      • original image
      • original image

      Everolimus was well tolerated in patients with advanced hepatocellular carcinoma, and 10 mg/day was defined as the phase 2 dosage. Preliminary antitumor activity was observed with everolimus in patients with advanced hepatocellular carcinoma, most of whom had prior systemic treatment.

    10. Lung Disease
      You have free access to this content
      Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes (pages 5103–5111)

      Ben-Xu Tan, Wen-Xiu Yao, Jun Ge, Xing-Chen Peng, Xiao-Bo Du, Ru Zhang, Bin Yao, Ke Xie, Long-Hao Li, Hang Dong, Feng Gao, Feng Zhao, Jian-Mei Hou, Jing-Mei Su and Ji-Yan Liu

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26151

      • original image
      • original image
      • original image

      The objective of this study was to evaluate the influence of metformin or insulin on the prognosis of patients with advanced nonsmall cell lung cancer (NSCLC) who also had type 2 diabetes and received first-line chemotherapy. The results suggested that metformin may improve the chemotherapy outcomes and survival of patients who have NSCLC with diabetes.

    11. You have free access to this content
      Do multidisciplinary team meetings make a difference in the management of lung cancer? (pages 5112–5120)

      Miriam M. Boxer, Shalini K. Vinod, Jesmin Shafiq and Kirsten J. Duggan

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26149

      Discussion of lung cancer patients at a multidisciplinary team meeting was associated with increased receipt of chemotherapy, radiotherapy, and referrals for palliative care. However, it did not improve survival.

    12. You have free access to this content
      Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer (pages 5121–5132)

      Mary-Clare Cathcart, Steven G. Gray, Anne-Marie Baird, Elaine Boyle, Kathy Gately, Elaine Kay, Robert Cummins, Graham P. Pidgeon and Kenneth J. O'Byrne

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26168

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Prostacyclin synthase (PGIS) expression is reduced/absent in human nonsmall cell lung cancer (NSCLC) protein samples (P < .0001) relative to matched controls, and is regulated both epigenetically and via post-translational mechanisms. Identifying mechanisms to block the post-translational down-regulation of PGIS may have clinical applications for the chemoprevention and/or treatment of NSCLC.

    13. Neuro-Oncology
      You have free access to this content
      Clinical course of adult patients with ependymoma : Results of the Adult Ependymoma Outcomes Project (pages 5133–5141)

      Terri S. Armstrong, Elizabeth Vera-Bolanos and Mark R. Gilbert

      Version of Record online: 28 APR 2011 | DOI: 10.1002/cncr.26181

      Diagnosis and treatment for adult patients with ependymoma are not standardized. Despite the low recurrence rate, patients report significant symptoms and disability.

    14. Discipline

      Complementary Medicine
      You have free access to this content
      Prevalence of complementary medicine use in a phase 1 clinical trials program : The MD Anderson Cancer Center Experience (pages 5142–5150)

      Aung Naing, Saneese K. Stephen, Moshe Frenkel, Chandtip Chandhasin, David S. Hong, Xiudong Lei, Gerald Falchook, Jennifer J. Wheler, Siqing Fu and Razelle Kurzrock

      Version of Record online: 28 APR 2011 | DOI: 10.1002/cncr.26164

      In a phase 1 clinical trial, the concurrent use of complementary and alternative medicine (CAM) in patients with advanced malignancies was evaluated. CAM usage was found to be common.

    15. Disparities Research
      You have free access to this content
      Colonoscopy screening rates among patients of colonoscopy-trained African American primary care physicians (pages 5151–5160)

      Sudha Xirasagar, Thomas G. Hurley, James B. Burch, Ali Mansaray and James R. Hébert

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26142

      • original image

      Training African American primary care physicians (PCPs) to perform colonoscopy safely and effectively improved screening rates among their African American and Medicaid patients. Colonoscopy-trained PCPs may help reduce colorectal cancer disparities.

    16. Epidemiology
      You have free access to this content
      Increased genetic susceptibility to intestinal-type gastric cancer is associated with increased activity of the RUNX3 distal promoter (pages 5161–5171)

      Byungho Lim, Hyoungseok Ju, Minjin Kim and Changwon Kang

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26161

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Genetic variations in the RUNX3 distal promoter were associated with susceptibility to intestinal-type gastric cancer by increasing promoter activity.

    17. Medical Oncology
      You have free access to this content
      A functional polymorphism (−1607 1G[RIGHTWARDS ARROW]2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer (pages 5172–5181)

      Li Liu, Jing Wu, Chen Wu, Ying Wang, Rong Zhong, Xinyu Zhang, Wen Tan, Shaofa Nie, Xiaoping Miao and Dongxin Lin

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26154

      • original image

      The results from this large case-control study and meta-analysis indicated that the matrix metalloproteinase-1 (MMP-1) −1607 single guanine (1G)-to-2G polymorphism (reference single nucleotide polymorphism 1799750) greatly increased the risk of development and progression of lung cancer.

    18. Outcomes Research
      You have free access to this content
      CT-guided percutaneous microwave ablation of adrenal malignant carcinoma : Preliminary results (pages 5182–5188)

      Xin Li, Weijun Fan, Liang Zhang, Ming Zhao, Zilin Huang, Wang Li, Yangkui Gu, Fei Gao, Jinhua Huang, Chuanxing Li, Fujun Zhang and Peihong Wu

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26128

      • original image
      • original image
      • original image

      CT-guided percutaneous water-cooled microwave ablation is a minimally invasive and effective method for the treatment of adrenal malignant tumors.

    19. Pediatric Oncology
      You have free access to this content
      Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCFβ-TRCP in neuroblastoma cells (pages 5189–5202)

      Akanksha Singh, Christopher Rokes, Monica Gireud, Stephen Fletcher, James Baumgartner, Greg Fuller, John Stewart, Peter Zage and Vidya Gopalakrishnan

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26145

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Retinoic acid elevated the expression of an S-phase kinase-associated protein 1/cullin 1/F-box (SCF) protein complex that contains the F-box protein β-transducin repeat-containing protein (β-TRCP) (SCFβ-TRCP) in neuroblastoma cells to promote repressor element-1 silencing transcription factor (REST) degradation and neuronal differentiation. The current results indicate that an impairment of this process may contribute to the failure of these tumors to differentiate in response to retinoic acid.

    20. Radiation Oncology
      You have free access to this content
      Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy (pages 5203–5211)

      Ye-Xiong Li, Qing-Feng Liu, Wei-Hu Wang, Jing Jin, Yong-Wen Song, Shu-Lian Wang, Yue-Ping Liu, Xin-Fan Liu, Li-Qiang Zhou and Zi-Hao Yu

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26167

      • original image
      • original image
      • original image
      • original image
      • original image

      Patients with early stage nasal NK/T-cell lymphoma have excellent locoregional control and favorable prognosis with radiotherapy, but patients with stage II disease or paranasal extension are at high risk of systemic failure, emphasizing the importance of integration of optimal radiotherapy with innovative systemic therapy. Prophylactic neck irradiation or central nervous system (CNS) chemoprophylaxis is not necessary, because of a very low incidence of cervical lymph node or CNS relapse.

    21. Symptom Control and Palliative Care
      You have free access to this content
      Patients rate physician communication about lung cancer (pages 5212–5220)

      Judith E. Nelson, Elizabeth B. Gay, Andrew R. Berman, Charles A. Powell, John Salazar-Schicchi and Juan P. Wisnivesky

      Version of Record online: 14 APR 2011 | DOI: 10.1002/cncr.26152

      • original image
      • original image

      Patients with lung cancer at all disease stages reported low rates of communication with their physicians about a broad range of topics that had an impact on care, from goals and preferences for treatment to physical, emotional, practical, and spiritual needs.

    22. Translational Research
      You have free access to this content
      Expression and function role of DNA methyltransferase 1 in human bladder cancer (pages 5221–5233)

      Chun-Te Wu, Ching-Fang Wu, Chang-Hsien Lu, Cheng-Chia Lin, Wen-Cheng Chen, Paul-Yang Lin and Miao-Fen Chen

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26150

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      DNA methyltransferase 1 (DNMT1) could be a significant clinical predictor for stage and treatment response of bladder cancer. The epidermal growth factor receptor-mediated phosphatidylinositol 3′-kinase–protein kinase B pathway might be the mechanism underlying the effects of DNMT1 on bladder cancer.

    23. You have free access to this content
      Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma (pages 5234–5244)

      Bryan M. Burt, Scott J. Rodig, Tamara R. Tilleman, Andrew W. Elbardissi, Raphael Bueno and David J. Sugarbaker

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26143

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Using tissue microarrays and immunohistochemistry, flow cytometry, and statistical analyses, the authors demonstrated a correlation between myeloid lineage immune cells and survival in large cohorts of patients with malignant pleural mesothelioma (MPM). Higher preoperative circulating monocyte counts are associated with poor survival in nonepithelial mesothelioma. Both may enable novel targets for immunotherapy.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Reply to risk of mortality in patients with cancer who experience febrile neutropenia (page 5246)

      Gary H. Lyman, Shannon L. Michels and Rich Barron

      Version of Record online: 23 MAY 2011 | DOI: 10.1002/cncr.26140

SEARCH

SEARCH BY CITATION